

The study entitled "**Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma**" was registered by Bayer under EudraCT number **2007-002365-13** but sponsored and conducted by Leiden University Medical Center in the Netherlands.

The study results were summarized in a peer reviewed publication by the investigators <http://www.ncbi.nlm.nih.gov/pubmed/?term=19773371>.